evipedia.ai
← Back

Ellagic Acid for Health & Longevity

Evidence Review created on 09/20/2026 using AI4L / Opus 5

Also known as: EA, Benzoaric Acid, Elagostasine, Gallogen, Lagistase

Motivation

Ellagic acid is a plant compound found in pomegranates, walnuts, strawberries, raspberries, chestnuts and oak-aged wines, where it mostly sits locked inside larger molecules called ellagitannins. Interest in it rests on a curious detail of human biology: very little ellagic acid ever reaches the bloodstream intact, and much of what the body appears to gain from ellagitannin-rich foods seems to come from what gut bacteria make out of it instead.

Pomegranate and its extracts have been used in traditional medicine for centuries, and ellagic acid is now sold on its own as an oral supplement, usually at doses well above what an ordinary diet supplies. Only part of the population carries the gut bacteria needed for the key conversion step, which is one reason different people respond very differently to the same amount.

This review examines what controlled human research shows about oral ellagic acid across blood fats, liver health and blood sugar; where that evidence is contested; what is known about its safety, its interactions and its sourcing; and how it is dosed and monitored in practice.

Benefits - Risks - Protocol - Conclusion

High-level overviews of ellagic acid and the gut-derived pathway that carries most of its proposed effects.

No directly relevant content was found for three priority experts. Searches of peterattiamd.com and hubermanlab.com returned only passing mentions inside broader supplement discussions, with no article or episode devoted to ellagic acid or its metabolite; hubermanlab.com’s only dedicated page is an AI-generated reference entry, which is excluded here. Chris Kresser’s site covers ellagic acid only as one example within a general article on phytochemicals, which does not meet the depth bar for this section.

Grokipedia

  • Ellagic acid

    Reference overview of the compound’s chemistry, natural sources, metabolism into urolithins and the research literature, useful as a fast orientation to structure and terminology before reading trial data.

Examine

  • Ellagic Acid

    Graded evidence summary written by Kamal Patel, covering 419 trial participants and one meta-analysis, with per-outcome grades for blood glucose and cardiovascular markers rather than narrative claims.

ConsumerLab

ConsumerLab has no product review or article dedicated to ellagic acid. A direct site search returns only reviews of ellagitannin-containing products such as pomegranate, acai and amla, in which ellagic acid appears as a constituent rather than as the subject, and regulatory warning entries in which it appears as one of many ingredients named in United States Food and Drug Administration letters.

Systematic Reviews

Pooled analyses of ellagic acid covering metabolic, glycemic and skeletal outcomes in randomized controlled trials (studies in which participants are assigned by chance to the compound or to a placebo) and in animal models.

The claimed-effect side of the trade-off is well represented above. The risk side is not: no systematic review or meta-analysis of the safety or adverse-event profile of ellagic acid supplementation has been published, so that half of the picture is unrepresented in this literature.

Mechanism of Action

Ellagic acid is a four-ring dilactone of hexahydroxydiphenic acid, released in the gut when ellagitannins from Punica granatum and similar plants are hydrolysed. It is very poorly soluble and very poorly absorbed: peak blood levels appear about one hour after intake, are low, and fall away within hours, with a terminal half-life (the time for blood levels to halve) of roughly eight hours. In healthy volunteers fed ellagitannin-rich fruit, under one percent of intake appears in plasma and urine as the parent compound (Stoner et al., 2005).

The unabsorbed remainder reaches the colon, where Gordonibacter and Ellagibacter species convert it into urolithins. These are absorbed far better, are conjugated by glucuronidation and sulfation (phase II tagging that prepares compounds for excretion), and circulate for one to two days. The compound is not receptor-selective; it distributes mainly to gut, liver and kidney tissue, with little reaching the brain.

Two competing explanations exist. The classical account credits direct antioxidant activity. The rival account holds that the parent compound is largely a delivery vehicle, because neither it nor punicalagin was detectable in plasma after pomegranate juice, while the urolithin metabolites that did circulate proved to be weak antioxidants (Cerdá et al., 2004). The signalling effects credited to both are activation of Nrf2 (a switch that turns on the cell’s own antioxidant enzymes), suppression of NF-κB (a master switch for inflammatory genes), and modulation of PPAR pathways (regulators of fat storage and burning).

Historical Context & Evolution

Ellagic acid was first described in the early nineteenth century by Michel Eugène Chevreul, who coined the name by reversing the French word for gall nut, the tannin-rich source from which he obtained it. For over a century it was a chemical curiosity of the tanning and dye industries rather than a candidate therapy.

Its first substantial biomedical use was diagnostic rather than therapeutic. In the 1950s and 1960s it was found to activate the contact limb of the clotting cascade, and it became the standard activating agent in reagents used to measure clotting time, a role it still holds in hospital laboratories today. That property also prompted early interest in it as a bleeding-control agent, which never reached routine practice.

Interest in health optimization arrived through cancer chemoprevention. From the 1980s onward, work at Ohio State University on freeze-dried black raspberries identified ellagic acid as a leading candidate constituent, and human pharmacokinetic work followed (Stoner et al., 2005). Those findings were real and reproducible in cell and rodent models; what they did not deliver was a human cancer outcome, and no controlled trial has since tested one.

The picture shifted rather than collapsed. Spanish work from 2004 showed the parent compound barely circulates (Cerdá et al., 2004), redirecting attention to its gut metabolites, and the 2016 demonstration that urolithin A induces mitophagy (Ryu et al., 2016) pulled the field toward longevity. Whether the parent compound or the metabolite is the correct unit of study remains open.

Expected Benefits

Benefits below are framed for readers who already track blood fats, blood sugar, inflammation and liver markers and are willing to test, dose and re-test; population-average framing is not used.

High 🟩 🟩 🟩

Improved Blood Lipid Profile

Oral ellagic acid lowers triglycerides across human randomized controlled trials, and raises HDL cholesterol in the larger of the two pooled analyses. Two independent meta-analyses published a year apart agree on the triglyceride direction; only one finds an HDL rise, the other reporting no significant HDL change (Wang et al.; Settakorn et al.). The proposed mechanism is reduced fat production in the liver together with improved fat clearance. Most participants had metabolic abnormalities at baseline, so anyone already sitting at optimal lipid values should expect a smaller shift.

Magnitude: In humans the pooled effect was a standardized mean difference (an effect size expressed in standard deviations) of −0.58, with a 95% confidence interval (the range likely to contain the true effect) of −0.87 to −0.29, for triglycerides, and +0.72 (0.37 to 1.07) for HDL cholesterol (Settakorn et al.).

Reduced Liver Fat and Liver Enzymes in Fatty Liver Disease

Ellagic acid reduces liver fat and circulating liver enzymes in metabolic dysfunction-associated steatotic liver disease (fat accumulation in the liver alongside metabolic abnormalities). Two randomized placebo-controlled trials support it: one measured liver fat and stiffness by imaging (Azar et al.), the other measured enzyme levels (Mighani et al.). Both ran eight weeks. One gave a calorie-restricted diet to both arms, so the diet raises the response in each group without inflating the difference against placebo.

Magnitude: Against placebo over eight weeks, the imaging index of liver fat fell by 0.23, liver stiffness by 0.47 kilopascals and alanine aminotransferase, ALT (an enzyme released by injured liver cells), by 27.9 units per litre (Azar et al.).

Medium 🟩 🟩

Lower Inflammatory Markers

Trials report falls in C-reactive protein (a blood marker of general inflammation), tumour necrosis factor alpha and interleukin-6 (two signalling proteins that drive inflammation) after eight weeks (Ghadimi et al.; Kazemi et al.). The proposed mechanism is suppression of NF-κB. These are risk markers rather than clinical events, and no trial has followed participants to a disease outcome, which is what holds the grade at Medium rather than higher.

Magnitude: High-sensitivity C-reactive protein fell by 0.81 milligrams per litre against placebo over eight weeks (Azar et al.).

Reduced Depressive Symptoms in Multiple Sclerosis

A triple-blind randomized trial gave 180 milligrams daily for twelve weeks to people with multiple sclerosis and mild to moderate depressive symptoms, and recorded lower scores on the Beck Depression Inventory-II (a validated depression questionnaire) alongside higher brain-derived neurotrophic factor and serotonin (Hajiluian et al.). One fifty-participant trial in a single disease population caps the grade; mood effects in people without a neurological condition are untested.

Magnitude: The direction is a fall in depression-questionnaire scores over twelve weeks in people with multiple sclerosis and baseline depressive symptoms, reported as statistically significant against placebo at p = 0.001; the trial publishes no between-group point difference.

Improved Sleep Quality and Bowel Symptoms in Irritable Bowel Syndrome

Two months of 180 milligrams daily improved Pittsburgh Sleep Quality Index scores (a validated sleep questionnaire) and irritable bowel severity scores against placebo in 44 patients (Mirzaie et al.). The proposed mechanism is reduced oxidative stress and lower gut inflammation. This rests on one small single-centre trial and has not been repeated, nor tested in people without bowel symptoms.

Magnitude: The direction is improvement in both sleep and symptom-severity scores after two months in irritable bowel syndrome, reported as significant at p < 0.05; the trial publishes no between-group point estimate.

Improved Cognitive Performance in Middle-Aged Overweight Men

A placebo-controlled trial gave 50 milligrams daily for twelve weeks to 150 middle-aged men and recorded better scores on the Wechsler Adult Intelligence Scale-Revised and the Montreal Cognitive Assessment (two validated cognitive tests) in the overweight participants only, alongside higher brain-derived neurotrophic factor and lower salivary cortisol (Liu et al.). A critical review of the neuroprotection literature reports reduced brain inflammation and preserved memory in rodents on the same pathways (Gupta et al.). One trial in one population caps the grade.

Magnitude: The direction is better scores on both cognitive tests over twelve weeks in overweight participants, with brain-derived neurotrophic factor up 21.2 percent and salivary cortisol down 22.7 percent; the trial publishes no between-group point difference for the test scores.

Reduced Chemotherapy Toxicity in Advanced Prostate Cancer ⭕️ Not Central to Health & Longevity

A randomized trial added oral ellagic acid to standard chemotherapy in men with prostate cancer no longer responding to hormone treatment, and recorded less systemic toxicity, significant for neutropenia (a shortage of the white cells that fight bacterial infection), alongside better tumour, symptom and blood-marker response (Falsaperla et al.). The proposed mechanism is antioxidant protection of healthy tissue during cytotoxic treatment. Survival did not differ. One small single-centre trial caps the grade. This bears on tolerating cancer treatment, not on lifespan.

Magnitude: Men given ellagic acid completed a mean of 6.5 chemotherapy cycles, range 5 to 11, against 4 cycles, range 3 to 8, on chemotherapy alone, with a significant fall in neutropenia and no difference in overall or progression-free survival.

Low 🟩

Improved Blood Sugar Control and Insulin Sensitivity ⚠️ Conflicted

Individual trials in type 2 diabetes and polycystic ovary syndrome report lower fasting glucose, insulin and HbA1c (average blood sugar over about three months) (Ghadimi et al.). One meta-analysis found a pooled benefit, a second found none in humans (Settakorn et al.). Net: the human effect is unresolved.

Magnitude: Pooled analyses split. One reports reduced fasting glucose (p = 0.008) and a lower insulin resistance index (p = 0.003) (Wang et al.); the other reports no significant human effect on glucose, insulin or insulin resistance (Settakorn et al.). Neither publishes a between-group outcome figure for these endpoints in people.

Reduced Waist Circumference ⚠️ Conflicted

Pooled human data show central fat falling without accompanying weight loss, consistent with improved fat handling in the liver. The two meta-analyses disagree: one finds a significant reduction (Settakorn et al.), the other none (Wang et al.). Net: the human effect is unresolved.

Magnitude: The pooled human effect was a standardized mean difference of −0.55, with a 95% confidence interval of −1.06 to −0.44 (Settakorn et al.); the competing analysis reports no significant change in waist circumference, body weight or body mass index (Wang et al.).

Reduced Ultraviolet-Induced Skin Pigmentation ⭕️ Not Central to Health & Longevity

A placebo-controlled trial gave 100 or 200 milligrams daily of ellagic acid from pomegranate extract for four weeks and measured less skin darkening after ultraviolet exposure (Kasai et al.). Exposure was an extract, not the isolated compound. This bears on skin appearance and photodamage, not lifespan.

Magnitude: Loss of skin brightness was inhibited by 1.35 percent at 100 milligrams daily and 1.73 percent at 200 milligrams daily relative to placebo over four weeks.

Speculative 🟨

Mitochondrial Renewal Through Urolithin A

Ellagic acid is the precursor of urolithin A, which triggers removal of damaged mitochondria. Human outcome data exist for supplemental urolithin A, not for ellagic acid itself (Kuerec et al.).

Bone Preservation

A systematic review of thirteen preclinical studies found improved bone density and strength with ellagic acid in animal models of osteoporosis (Gholizadeh et al.). No human trial exists; the basis is animal and cell work.

Cancer Chemoprevention

A review of the experimental evidence describes ellagic acid blocking cell proliferation, invasion and angiogenesis (the growth of new blood vessels feeding tumours) (Čižmáriková et al.). The basis is cell-culture and rodent data only.

Benefit-Modifying Factors

  • Urolithin metabotype: Only about 40 to 50 percent of adults carry the gut bacteria that convert ellagic acid to urolithin A. Non-producers reach far lower metabolite exposure and are the most plausible explanation for null results in pooled human analyses.

  • Conjugating enzyme variation: Activity of UGT1A10 and related glucuronidation enzymes (they attach sugar groups to metabolites for excretion) sets how much unconjugated urolithin reaches tissue. Variation here shifts exposure independently of dose.

  • Baseline biomarker levels: Every positive trial enrolled people with raised triglycerides, glucose or liver enzymes. Effects scale with starting derangement, so those already at optimal values have less headroom and should expect smaller changes.

  • Sex-based differences: A controlled oral-delivery study in animals found sex-dependent differences in ellagic acid bioavailability, urolithin production and gut microbiota response (Ávila-Gálvez et al.). Human trials have not been powered to separate men from women.

  • Pre-existing health conditions: Metabolic syndrome, fatty liver, polycystic ovary syndrome and type 2 diabetes are the states in which benefit has been demonstrated. Bowel disease that alters colonic flora would be expected to reduce conversion and therefore effect.

  • Age-related considerations: Conversion capacity tracks microbiome composition, which shifts with age and antibiotic history. Older adults at the upper end of the target range are both more often non-producers and more often carrying the raised baseline markers that predict response.

Potential Risks & Side Effects

Risks below are framed for readers who stack several metabolic agents and monitor their own laboratory markers; the relevant question is interaction and interference, not population-average safety.

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been documented in more than one controlled human trial, since the randomized trials of ellagic acid report adverse events only as unremarkable and without between-group differences.

Medium 🟥 🟥

No risk reaches Medium either: the single trial showing a validated blood marker moving in a harmful direction tested a polyphenol mixture rather than isolated ellagic acid, and its direction conflicts with the trials of the isolated compound.

Low 🟥

Rise in Circulating Cholesterol and Triglycerides ⚠️ Conflicted

In a crossover trial, postmenopausal women taking a polyphenol mixture supplying 312 milligrams of ellagitannins plus ellagic acid daily showed higher total cholesterol, LDL cholesterol and triglycerides, while oxidised LDL cholesterol fell (García-Nicolás et al.). Trials of the isolated compound show the opposite. Net: unresolved and probably mixture-specific.

Magnitude: Over eight weeks total cholesterol rose 7 percent, LDL cholesterol 9.5 percent and triglycerides 16 percent, in roughly 80 percent of 78 completers, with larger rises at older ages.

Allergic Contact Dermatitis

Patch testing identified ellagic acid as the sensitising agent behind a severe delayed skin reaction after repeated handling of Melianthus comosus plant material (Arora et al.). This is the first proven case, and it concerns skin contact rather than oral intake. Lesions cleared within one to two weeks of avoidance.

Magnitude: Not quantified in available studies. Only a single patch-test-confirmed case report exists, so no prevalence or incidence figure has ever been measured.

Additive Blood Sugar Lowering Alongside Glucose-Lowering Therapy

Pooled human trials show ellagic acid lowering fasting glucose and insulin resistance (Wang et al.), so adding it on top of existing therapy could push readings below target. No trial has enrolled people on intensive glucose-lowering treatment, and none has recorded hypoglycaemia (abnormally low blood sugar) as an endpoint.

Magnitude: The direction is downward movement in glucose, which matters only when glucose-lowering drugs are already in use; the literature reports no hypoglycaemia rate for ellagic acid at any dose.

Speculative 🟨

Topoisomerase II Inhibition

Ellagic acid and hydroxylated urolithins inhibit both forms of human topoisomerase II, an enzyme that untangles DNA during cell division (Furlanetto et al.). The basis is cell-free assay data only.

Altered Drug-Metabolising Enzyme Activity

In colon cells ellagic acid induced CYP1A1 (an enzyme that processes drugs and toxins) and inhibited sulfotransferases (enzymes that tag compounds for excretion). Oral dosing did not reproduce this in rats (González-Sarrías et al.).

Contact-Pathway Coagulation Activation

Ellagic acid is the standard activator of the contact clotting pathway in laboratory clotting-time reagents, and injected doses produced vascular and blood-cell changes in rats (Damas et al.). No oral human signal has been reported.

Organ Injury at Very High Doses

An acute study gave rats 200 to 2,000 milligrams per kilogram orally and found dose-dependent heart, kidney and lung injury alongside inhibited kidney mitochondrial respiration (Hurtado-Nuñez et al.). The basis is animal data only.

Risk-Modifying Factors

  • Genetic and microbial conversion status: Non-producers of urolithin A reach lower metabolite exposure, which lowers both expected benefit and any metabolite-mediated risk. Conversion status is the single largest source of between-person variability in exposure.

  • Baseline biomarker levels: Low baseline fasting glucose raises the relevance of the additive glucose-lowering risk, while an already optimal lipid panel leaves little room for benefit and shifts the risk-benefit balance unfavourably.

  • Sex-based differences: Animal work shows sex-dependent differences in absorption and urolithin output (Ávila-Gálvez et al.). No human trial has reported adverse events separately by sex, so any sex-specific risk signal would currently be invisible.

  • Pre-existing health conditions: Bleeding disorders, active peptic ulceration and advanced liver or kidney impairment concentrate the theoretical coagulation and clearance concerns. Diagnosed diabetes on active therapy concentrates the glucose-lowering concern.

  • Age-related considerations: Older adults carry more polypharmacy, more antiplatelet and anticoagulant use, and more age-related decline in drug clearance, so the interaction risks matter more at the upper end of the target range than the intrinsic ones.

Key Interactions & Contraindications

  • Glucose-lowering drugs (metformin, glipizide, glimepiride, insulin): Caution. Additive glucose lowering may drive readings below target. Mitigation: check fasting glucose weekly for the first month after starting and adjust drug dosing with the prescribing clinician.

  • Anticoagulants and antiplatelets, drugs that slow clotting (warfarin, apixaban, rivaroxaban, clopidogrel): Caution, based on mechanism rather than human data. The compound activates the contact clotting pathway in vitro. Mitigation: no combined use without clotting-time monitoring at four weeks.

  • CYP1A1 and CYP1A2 substrates (caffeine, theophylline, tizanidine, melatonin): Caution, theoretical. CYP1A2 clears these drugs in the liver. Enzyme induction seen in colon cells did not reproduce with oral dosing in rats. Mitigation: separate doses by four hours and watch for altered drug effect.

  • Systemic antibiotics (amoxicillin, ciprofloxacin, doxycycline): Monitor. A course eliminates the Gordonibacter and Ellagibacter species that produce urolithins, abolishing metabolite exposure. Mitigation: expect no effect during and for some weeks after a course.

  • Over-the-counter iron salts and antacids (ferrous sulfate, calcium carbonate, magnesium hydroxide): Caution. Tannin-type compounds bind divalent metals and reduce their absorption. Mitigation: separate ellagic acid and mineral doses by at least two hours.

  • Over-the-counter analgesics (aspirin, ibuprofen, naproxen): Caution. These already impair platelet function or irritate gastric mucosa, compounding the theoretical bleeding concern. Mitigation: avoid routine daily combination; occasional use requires no specific action.

  • Supplements with additive glucose lowering (berberine, chromium picolinate, cinnamon extract, alpha-lipoic acid): Caution. Stacked glucose lowering can overshoot. Mitigation: introduce one agent at a time, four weeks apart, with fasting glucose measured between introductions.

  • Supplements with additive bleeding risk (fish oil, Ginkgo biloba, high-dose vitamin E, nattokinase): Caution. Theoretical additive effect on clotting. Mitigation: pause all of them at least seven days before any planned surgical or dental procedure.

  • Supplemental urolithin A (Mitopure and equivalents): Monitor for redundancy rather than harm. Taking both delivers the same downstream metabolite twice. Mitigation: choose one, and prefer the metabolite if producer status is negative.

  • Probiotic and prebiotic products: Potentiating. Fermentable fibre and certain strains increase urolithin output from the same ellagic acid dose. Mitigation: none needed; this is a deliberate way to raise metabolite exposure.

  • Other interventions: Calorie restriction, potentiating. Combined with ellagic acid in one trial (Azar et al.), the effect on liver fat was additive. Mitigation: none needed. No interference with fasting protocols, sauna or exercise programmes has been reported.

Populations who should avoid Ellagic Acid:

  • People with a documented contact allergy or hypersensitivity to ellagic acid or pomegranate-derived extracts
  • People with an inherited or acquired bleeding disorder, or on anticoagulation with an international normalised ratio target above 2.5
  • People within 14 days of scheduled surgery, dental extraction or an invasive procedure
  • People with advanced liver disease at Child-Pugh Class C
  • People with an estimated glomerular filtration rate, eGFR (a measure of kidney filtering capacity), below 30 mL/min/1.73 m²
  • Pregnant or breastfeeding women, in whom no safety data of any kind exist
  • People under 18 years of age, who have never been enrolled in a trial of this compound

Risk Mitigation Strategies

  • Establish producer status first: A urinary urolithin measurement after five days of pomegranate or walnut intake separates producers from non-producers, so non-converters avoid months of contact-allergy and additive glucose-lowering exposure with no prospect of benefit.

  • Start at 100 to 180 milligrams daily: The lowest dose used in successful trials. Starting here rather than at 1,000 milligrams limits exposure while response is unknown, and keeps the additive glucose-lowering risk small.

  • Weekly fasting glucose for four weeks: For those on metformin, a sulfonylurea (a class of oral blood-sugar-lowering drugs) or insulin, weekly readings confirm that glucose stays above 70 mg/dL, catching the additive lowering effect before symptoms appear.

  • Stop seven days before any procedure: A one-week washout well exceeds the eight-hour half-life and clears circulating urolithin conjugates, neutralising the theoretical contact-pathway clotting concern around surgery or dental work.

  • Separate from iron and mineral doses by two hours: Tannin-type binding reduces absorption of iron, calcium and magnesium. Time separation preserves mineral status without abandoning either supplement.

  • Recheck the lipid panel at eight to twelve weeks: This catches the conflicting cholesterol signal seen with polyphenol mixtures, so any unexpected rise in LDL cholesterol or triglycerides is detected rather than assumed away.

  • Use extracts with a stated ellagic acid percentage: A knowable delivered dose keeps the additive glucose-lowering risk bounded and stops an unlabelled over-strength extract from pushing intake far above the doses at which safety was observed.

Therapeutic Protocol

  • Standard dose: 180 to 200 milligrams daily of isolated ellagic acid, the dose used in most positive randomized trials of the compound, taken for a minimum of eight weeks before any assessment of response.

  • Higher-dose regimen: 500 milligrams twice daily of pomegranate extract standardised to 90 percent ellagic acid for twelve weeks, the regimen under test at the University of Guadalajara in metabolic syndrome.

  • Whole-food approach: Roughly one cup of pomegranate arils, 30 grams of walnuts or a cup of raspberries daily. Popularised by Gary Stoner’s berry chemoprevention work at Ohio State University.

  • Metabolite-first approach: 500 to 1,000 milligrams daily of urolithin A, bypassing conversion entirely. Developed commercially by Amazentis, whose founders Johan Auwerx and Chris Rinsch produced the original mitophagy work.

  • Best time of day: No trial has compared morning with evening dosing. Trials specified daily intake with meals, so the practical rule is the largest meal of the day, for bile-assisted absorption of a poorly soluble compound.

  • Half-life: Roughly eight hours for the parent compound, with peak levels at about one hour; the urolithin conjugates that carry most activity persist for 24 to 48 hours.

  • Single versus split dosing: Trials at 180 milligrams used a single daily capsule; the multiple sclerosis trial split 180 milligrams into two 90-milligram doses, and the 1,000-milligram regimens are split morning and evening.

  • Genetic and microbial factors: Conversion depends on carriage of Gordonibacter and Ellagibacter, not on a human gene. Variation in UGT1A10 glucuronidation capacity further shifts how much active metabolite reaches tissue.

  • Sex-based differences: Animal work shows different bioavailability and urolithin output by sex (Ávila-Gálvez et al.). No human dose adjustment by sex is established, and no trial has been powered to find one.

  • Age-related considerations: Doses were identical across adult age ranges in all trials. Older adults are more often non-producers, so confirming conversion status matters more at the upper end of the target range than adjusting the dose.

  • Baseline biomarker levels: Raised triglycerides, fasting glucose or liver enzymes predict measurable response. Those at optimal baselines can expect little, and the metabolite-first approach is the more rational route for mitochondrial goals.

  • Pre-existing health conditions: Fatty liver, metabolic syndrome, polycystic ovary syndrome and type 2 diabetes are the states with demonstrated response. Recent antibiotic use predicts no response regardless of condition.

Discontinuation & Cycling

  • Intended duration: Every published trial ran eight to twelve weeks. Nothing establishes an appropriate lifelong duration, so continued use past twelve weeks is an extrapolation rather than a tested protocol.

  • Withdrawal effects: None documented. No trial reported rebound in glucose, lipids, liver enzymes or inflammatory markers after the intervention period ended, and no dependence mechanism is plausible.

  • Tapering: Not applicable. With an eight-hour half-life and no receptor downregulation, abrupt cessation is the tested pattern in every trial and carries no known consequence.

  • Cycling for efficacy: Untested. No trial has compared continuous with intermittent dosing, and no tolerance mechanism has been described, so any cycling schedule is arbitrary rather than evidence-based.

  • Confirming benefit before continuing: Stopping for four weeks and re-measuring the markers that moved distinguishes a genuine response from drift or from concurrent diet change.

Sourcing and Quality

  • Form of the raw material: Products are either pomegranate extract standardised to 40 or 90 percent ellagic acid, or synthetic ellagic acid. The standardised percentage, not the capsule weight, determines the delivered dose.

  • Label arithmetic: A 500-milligram capsule of 40 percent extract supplies 200 milligrams of ellagic acid. Labels that state extract weight without a standardisation percentage make the actual dose unknowable.

  • Third-party testing: Botanical extracts carry heavy-metal and adulteration risk. Certification by NSF International, USP or Informed Choice, with a batch certificate of analysis available, is the practical check.

  • Formulation and solubility: Ellagic acid is very poorly water-soluble. A formulation review finds that phospholipid complexes, nanoemulsions and cyclodextrin carriers raise absorption substantially in laboratory work (Nyamba et al.), though no trial has compared them head to head in people.

  • Reputable suppliers: Life Extension, Thorne, NOW Foods and Swanson publish batch testing for their pomegranate extracts. For the metabolite route, Timeline’s Mitopure is the material used in the published urolithin A trials.

  • Compounding pharmacies: Rarely relevant here. The compound is not a prescription drug, so compounded preparations offer no purity advantage over a third-party-tested commercial extract.

Practical Considerations

  • Time to effect: Liver enzymes, triglycerides and inflammatory markers moved over eight weeks in trials. Nothing is detectable at two weeks, and an assessment before eight weeks will read as failure regardless of true response.

  • Common pitfall, ignoring conversion status: Roughly half of adults cannot produce urolithin A. Taking the parent compound without checking predicts months of non-response that gets misread as poor product quality.

  • Common pitfall, dosing from marketing claims: Extract weight is routinely confused with ellagic acid content, so a nominal 500-milligram product may deliver 200 milligrams or less of the active compound.

  • Common pitfall, expecting mitochondrial effects: The muscle and mitochondrial findings belong to supplemental urolithin A, not to ellagic acid. The parent compound has no human data on strength, endurance or mitochondrial function.

  • Regulatory status: Regulated as a dietary supplement in the United States, with no approved drug indication anywhere. The Food and Drug Administration issued warning letters in 2008 to sellers marketing ellagic acid products as cancer cures.

  • Cost and accessibility: Widely available and inexpensive at roughly 10 to 25 US dollars a month. Urolithin A supplements cost roughly 100 dollars a month; neither is reimbursed by any insurer or national health system.

Interaction with Foundational Habits

  • Sleep: Direct and favourable. A randomized trial recorded improved sleep-quality scores after two months at 180 milligrams daily in people with irritable bowel syndrome (Mirzaie et al.), plausibly through reduced gut inflammation. No stimulant effect has been reported, so evening dosing carries no known penalty.

  • Nutrition: Direct and two-way. Pomegranate, walnuts, raspberries, strawberries, chestnuts, pecans and oak-aged wine supply ellagitannins. Fermentable fibre feeds the bacteria that make urolithins, so a high-fibre pattern raises metabolite output from the same dose. Taking capsules with a fat-containing meal aids absorption of a poorly soluble compound.

  • Exercise: Potentiating in principle, unproven in fact for the parent compound. Mitophagy and mitochondrial biogenesis are complementary, and the metabolite has shown muscle-endurance effects in the human trials collected by a systematic review (Kuerec et al.), but no exercise trial has tested ellagic acid itself. No blunting of training adaptation has been reported.

  • Stress management: Indirect. Serum cortisol fell alongside depression scores in the multiple sclerosis trial (Hajiluian et al.), suggesting an anti-inflammatory route rather than direct action on the stress axis. Nothing suggests interference with breathing practice, meditation or sauna protocols.

Monitoring Protocol & Defining Success

Baseline testing establishes whether there is anything for ellagic acid to move. Because the documented effects cluster in blood fats, blood sugar, inflammation and liver enzymes, a useful baseline panel covers a fasting lipid panel, fasting glucose and insulin, HbA1c, high-sensitivity C-reactive protein and a liver panel. A urinary urolithin measurement taken after five days of pomegranate or walnut intake classifies producer status and predicts who can respond at all.

Ongoing testing is repeated at 8 to 12 weeks, matching the duration of every published trial, then at 6 months, then every 6 to 12 months if use continues. The 8 to 12 week point is where a genuine responder separates from a non-responder, and unchanged markers there indicate no biochemical response rather than a need for patience. Liver enzymes warrant the same cadence in anyone with existing liver disease.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Triglycerides Below 80 mg/dL Most consistent responder across both meta-analyses 12-hour fast required; conventional cut-off is a far looser 150 mg/dL
HDL cholesterol Above 60 mg/dL The second lipid marker that moved in pooled human data Pair with triglycerides; conventional thresholds are 40 mg/dL for men and 50 mg/dL for women
LDL cholesterol 70 to 100 mg/dL Detects the conflicting upward signal seen with polyphenol mixtures Direct measurement preferred over calculation when triglycerides are high
Fasting glucose 75 to 86 mg/dL Safety check for additive lowering alongside glucose-lowering drugs Conventional range runs to 99 mg/dL; draw before 9 a.m. after a 10-hour fast
HbA1c 4.8 to 5.3% Confirms whether any glucose change is real or day-to-day noise No fasting needed; conventional threshold for concern is 5.7%
Fasting insulin 2 to 5 µIU/mL Tracks insulin resistance, the endpoint the two meta-analyses dispute Conventional reference ranges run to 25 µIU/mL; must be drawn fasting alongside glucose so the resistance index can be calculated
High-sensitivity C-reactive protein Below 0.5 mg/L The inflammatory marker that fell most consistently in trials Conventional low-risk cut-off is 1.0 mg/L; invalid within two weeks of any infection
ALT 10 to 26 U/L for men, 8 to 22 U/L for women Primary liver readout in the fatty liver trials Conventional upper limits of 40 to 55 U/L are far too permissive for this purpose
GGT Below 20 U/L for men, below 15 U/L for women Second liver enzyme, and a sensitive marker of oxidative stress Gamma-glutamyl transferase; conventional upper limits of about 50 U/L for men and 35 U/L for women are far looser; rises with alcohol, so record intake alongside
Urinary urolithin A No established target; track presence or absence instead Classifies producer status and predicts whether response is possible Collect after five consecutive days of pomegranate or walnut intake; a one-off test is uninformative

Qualitative markers worth tracking alongside the laboratory panel:

  • Sleep quality and how rested mornings feel, the one subjective endpoint a trial actually measured
  • Bowel comfort, urgency and bloating, which improved alongside sleep in the same trial
  • Daytime energy and perceived effort during habitual training sessions
  • Mood stability, which moved in the only trial to measure it with a validated questionnaire
  • Skin tone and visible pigmentation after sun exposure, over a four-week horizon rather than days

Emerging Research

Trials below are selected for their bearing on whether a reader already dosing metabolic agents should keep, start or stop this one; several test the metabolite rather than the parent compound, which is noted in each case.

  • Ellagic acid in metabolic syndrome: NCT04011618 gave 500 milligrams of 90 percent pomegranate extract twice daily for 12 weeks to 32 adults, measuring waist circumference, blood pressure, insulin sensitivity and insulin secretion. Phase 2; results were submitted in 2025 but not yet posted.

  • Polyphenol metabotypes after menopause: NCT07182370 enrolled 90 postmenopausal women in a crossover design with 100 milligrams of daily ellagic acid inside a polyphenol mixture, with oxidised LDL as the primary endpoint. First results are already published (García-Nicolás et al.).

  • Urolithin A and glucose metabolism in older adults: NCT06274749, run by the National Institute on Aging, randomises 180 adults aged 55 and over to the metabolite rather than ellagic acid, measuring insulin secretion after an oral glucose load at 4 and 8 weeks.

  • Urolithin A before prostate surgery: NCT06022822, a Phase 2 National Cancer Institute trial in 90 men, tests the metabolite against placebo before radical prostatectomy with an oxidative DNA-damage marker as the primary endpoint. It is the nearest thing to a human test of the chemoprevention hypothesis.

  • Pomegranate juice in ulcerative colitis: NCT07115862 at the University of California, Los Angeles gives ellagitannin-rich juice to 30 patients, with a clinical activity index and faecal calprotectin as endpoints. This tests gut-level effects where ellagic acid concentrations are highest.

  • Where the case could weaken: The strongest counter-evidence is already published. A 2025 meta-analysis found no significant human effect on glucose, insulin or insulin resistance despite large animal effects (Settakorn et al.), and a polyphenol mixture raised circulating lipids in postmenopausal women (García-Nicolás et al., 2026).

  • The replication problem: Most positive trials of isolated ellagic acid come from one research group at Qazvin University of Medical Sciences (Ghadimi et al., 2021; Kazemi et al., 2021; Mighani et al., 2025). Independent replication outside that centre is the single most decisive piece of missing evidence.

  • Formulation as the next variable: A formulation review reports solubility-enhanced carriers raising absorption several-fold in laboratory work (Nyamba et al., 2021). If a trial ever compares an enhanced formulation against plain extract, current dose recommendations would need rewriting.

Conclusion

Ellagic acid is a plant compound from pomegranates, walnuts and berries that barely enters the bloodstream itself and appears to act mostly through what gut bacteria convert it into. That single fact organises everything else about it. Roughly half of adults lack the bacteria for it, the most likely reason human evidence looks strong in some analyses and empty in others.

The clearest human findings are in blood fats and in liver fat and liver enzymes, where separate trials and separate pooled analyses point the same way. Inflammation markers, mood, sleep and thinking ability have each moved in small trials. Blood sugar is genuinely disputed: pooled analyses reach opposite conclusions in people, though animal effects are large and consistent. Bone claims rest on animal work; cancer evidence is laboratory work plus one small trial in men already being treated.

The safety picture is quiet at tested doses. Controlled trials report no distinctive adverse effects; the documented concerns are a single skin-allergy case, laboratory enzyme effects that did not reproduce in living animals, organ injury in animals given far larger doses, and the possibility of adding to drugs that already lower blood sugar.

The evidence base is thin. Most positive trials of the isolated compound come from one research centre and run eight to twelve weeks, while much of the mitochondrial research concerns the gut-derived metabolite and has been funded and conducted by the company that sells it. Neither product is reimbursed, so the commercial interest sits with the manufacturers.

Top - Benefits - Risks - Protocol